Contact

Office: +31 242020020

info@screenpointmed.com

Technical support: +31 242020028

support@screenpointmed.com

Contact U.S.

Phone: 1-833-MammoAI (626-6624)

© 2019 by ScreenPoint Medical

Mammography has never been this clear

Best New Radiology Vendor

in EuroMinnies 2019

The AI solution for early detection and optimized workflow

Reading mammograms can be challenging, no matter what your experience level or patient volume is, and using most computer-assisted detection (CAD) solutions - even with artificial intelligence (AI) - can really slow you down. What if there were an AI solution that actually worked the way you do?

 

Transpara™ automatically categorizes the mammograms more likely to have cancerous lesions. It is a solution that clearly designates suspicious areas for closer inspection and will make your entire workflow easier to manage - without slowing you down.

Upcoming Events

RSNA,    1-6 December 2019, Chicago IL.

 
 
News
July 23, 2019 - Volpara Signs Distribution Agreement To Sell Transpara™, Screenpoint Medical's AI Solution For Breast Cancer Detection

Volpara Solutions and ScreenPoint Medical BV announced signature of an agreement under which Volpara will sell ScreenPoint's Transpara™ products to breast imaging clinics in the United States, Australia, New Zealand, and parts of Asia. Read the full press release

July 11, 2019 - Affidea Partners With ScreenPoint Medical to Increase Diagnostic Accuracy of Screening Mammography With the Use of AI

Affidea and ScreenPoint Medical announced a strategic partnership to streamline and improve the clinical performance of screening mammography and drive the earlier detection of breast cancer. The partnership will leverage Affidea's growing footprint in the European breast imaging marketplace and will provide a unique opportunity for ScreenPoint Medical to implement the innovative AI solution, Transpara™, in another three European countries - Greece, Hungary and Spain.

Read the full press release
March 6, 2019  -  Transpara AI software equals radiologists in study published in the Journal of the National Cancer Institute (JNCI) 

Deep learning software Transpara is shown to be robust and reliable in the largest AI study with screening mammograms to date. In a multi-center study, over 100 radiologists from the U.S. and Europe read series of mammograms from 4 different vendors giving a total of 28,296 independent interpretations. The detection performance of Transpara was better than the performance of over 60% of the radiologists. Read more about this groundbreaking study.

February 20, 2019  -  ScreenPoint Medical - Winner of the Best New Radiology Vendor in the Inaugural EuroMinnie Awards 2019
 

ScreenPoint Medical is honoured to be winner of the Best New Radiology Vendor in the inaugural EuroMinnie awards 2019. According to the announcement by Philip Ward, Editor in Chief of AuntMinnieEurope.com, "So many of the great achievements in radiology have their roots in Europe, so it's only fitting that we now have the EuroMinnies as a vehicle to recognize the European imaging community's many accomplishments."

Read the full press release

 
November 29, 2018  -  ScreenPoint Medical and Volpara Health Technologies Sign MOU to Partner in Bringing AI Breast Imaging Solutions to the Clinic

 

ScreenPoint Medical announced today that it has signed a Memorandum of Understanding (MOU) with Volpara Health Technologies. Volpara will deliver ScreenPoint’s AI-based products to customers as part of its expanding VolparaEnterprise AI cloud ecosystem. Together, the two companies expect to improve the clinical performance of mammography and drive the earlier detection of breast cancer. The partnership will leverage Volpara’s growing footprint in the breast imaging marketplace and will provide a unique opportunity for ScreenPoint to enter the US market.

Read the full press release

 

November 26, 2018  -  ScreenPoint Medical Receives FDA Clearance for AI Application Transpara™ to Assist Radiologists with Reading Screening Mammograms

 

ScreenPoint Medical, a medical imaging company developing artificial intelligence (AI) solutions for the early detection of breast cancer, announced today that it has received 510(k) Clearance from the U.S. Food & Drug Administration (FDA) for Transpara™ detection and decision support software, designed to assist radiologists with the reading of screening mammograms. Transpara is the first AI application for detecting breast cancer in screening mammograms to gain 510(k) Clearance from the FDA, based on its unique functionality which interactively provides support for detection and diagnosis. 

Read the full press release

 

November 20, 2018  -  Reader Study Evaluating Transpara™ AI Software for Improving Mammography Interpretation Published in Radiology  

 

Radiologists significantly improved their cancer detection in mammography without increasing reading times when using Transpara™ software from ScreenPoint Medical, according to results of a study published in Radiology. In the study, “Detection of breast cancer using mammography: Impact of an Artificial Intelligence support system,” researchers compared breast cancer detection performance of 14 radiologists conducting a single-read of 240 mammography exams to performance when supported by the Transpara artificial intelligence (AI) system.  Download the article here.

Read the full press release

 

22 September 2018  -  A Promising future for AI in breast cancer screening

 

A recently released report projects the world market for artificial intelligence (AI) and machine learning in medical imaging, including software for automated detection, quantification, decision support and diagnosis, will reach $2 billion by 2023. According to the report’s author, analyst Simon Harris, “The interest and enthusiasm for AI in the radiologist community has notably increased over the last 12 to 18 months and the discussion has moved on from AI as a threat to how AI will augment radiologists”.

Read the full press release

 

31 May 2018   -   ScreenPoint Closes Series B Investment Round to Accelerate Growth and Commercialization of Its AI Product  Transpara™ for Improving Mammogram Reading

 

ScreenPoint Medical announces today that it has raised €4.3 million in a new financing round to accelerate market introduction and further development of its products. The financing was led by Siemens Healthineers with additional participation of private investors.

Read the full press-release

 

30 May 2018  -  Siemens Healthineers and ScreenPoint Medical sign agreement to jointly develop AI-based applications in breast imaging

 

  • Strategic partnership aimed to enable personalized breast care pathways by leveraging artificial intelligence, from risk stratification to image acquisition and diagnosis

  • Innovative clinical and workflow applications to be jointly developed to help expand precision medicine 

 

Read the full press-release

 

14 May 2018   Release Transpara™ 1.4.0

 

This new release of Transpara™ includes a great new feature: Interactive Decision Support for Digital Breast Tomosynthesis. From now on, also DBT volumes can be fully analyzed with our artificial intelligence algorithms to find and characterize breast cancer. Additionally, the 2D mammography algorithms have been further improved achieving performance slightly better than an average radiologist.

 

January 2018    Transpara™ in Applied Radiology

 

Transpara™ has been mentioned in an article about: "RSNA 2017 Technology: Innovation in Abundance" , published in Applied Radiology. The article can be found here.

 

12 January 2018    Article in Image Technology News

 

An article about: "Transpara Deep Learning Software Matches Experienced Radiologists in Mammogram Reading" has been published in Image Technology News. The article can be found here or the pdf version.

 

13 December 2017    Transpara on Dutch national television

 

Transpara was shown during the NieuwsUur program on the Dutch national television on 13 December. The item can be found here (in Dutch).

 

30 November 2017    Bulletin: Deep Learning Shows Potential for Accurately Reading Mammograms

 

The use of deep learning (DL) technology could help radiologists increase the quality of breast cancer screening programs, lower costs, and reduce the variability in the cancer detection process. The full article can be read online here or downloaded here.

 

21 November 2017     Press release: ScreenPoint Medical Showcases Transpara™ at the RSNA

 

A press-release has been launched about the attendance of ScreenPoint Medical at the RSNA Annual Meeting in Chicago: ScreenPoint Medical will showcase Transpara™, software designed to assist radiologists with the reading of mammograms and digital breast tomosynthesis exams, at the upcoming 103rd Annual Radiological Society of North America (RSNA) meeting, November 26-December 1, 2017. (South Hall #3178). Exploiting Big Data, Deep Learning and the latest developments in Artificial Intelligence (AI), Transpara is based on innovative insights into how breast radiologists can best be supported to improve the efficiency and accuracy of reading mammograms.  The full article can be found here.

 

October 2017     Publication in DI Europe  October issue

 

A nice article in the October issue of Diagnostic Imaging Europe, about improving the detection of breast cancer with artificial intelligence. In the article, the benefits of using artificial intelligence in breast cancer screening is described as well as its potential. The article can be found here.

 

September 2017    Publication in MemoRad 2017-3

 

Artificial Intelligence in medical imaging is the central theme of the Autumn issue of MemoRAD. In this magazine, an article is published about ScreenPoint and our general ambition in developing Transpara™. The article can be read here in Dutch. An English version will follow soon.